This immunohistochemical approach, which is a valid resource for identification of tumoral targets accessible for therapy (i.e., CD117 in gastrointestinal stromal tumors [14] or HER2 in breast and gastric cancer [15, 16]), has not yet found an application in colorectal cancer. The gene discussed is ERBB2; the disease is gastrointestinal stromal tumor.